COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register

•Large anonymised clinical data collection of confirmed COVID-19 in MS patients from UK clinicians during the first two waves of the pandemic.•196 patients entered had a confirmed COVID-19 infection by clinical finding, PCR or antibody test.•Of the 85 patients hospitalised 63.5% were due to COVID-19...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis and related disorders 2021-11, Vol.56, p.103317-103317, Article 103317
Hauptverfasser: Middleton, RM, Craig, EM, Rodgers, WJ, Tuite-Dalton, K, Garjani, A, Evangelou, N, das Nair, R, Hunter, R, Tallantyre, EC, Cauchi, M, Cairn, C, Paling, D, Fuller, S, McDonnell, G, Petheram, K, Liu, B, Nock, U, Ingram, G, Brownlee, W, Taylor, J, Nicholas, R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Large anonymised clinical data collection of confirmed COVID-19 in MS patients from UK clinicians during the first two waves of the pandemic.•196 patients entered had a confirmed COVID-19 infection by clinical finding, PCR or antibody test.•Of the 85 patients hospitalised 63.5% were due to COVID-19, median stay in hospital was 9 days regardless of survival.•Patients with MS were less likely to be admitted to hospital in the second wave of the pandemic, the likelihood of death in this group also reduced.•Hospitalised patients in the second wave were more likely to be younger, less disabled, and not to have progressive MS.•Older, male patients with comorbidity, increased disability and progressive MS were associated with increased rates of hospitalisation, being on a DMT was associated with a lower likelihood of being admitted. In March 2020, the United Kingdom Multiple Sclerosis Register (UKMSR) established an electronic case return form, designed collaboratively by MS neurologists, to record data about COVID-19 infections in people with MS (pwMS). Examine how hospital admission and mortality are affected by disability, age and disease modifying treatments (DMTs) in people with Multiple Sclerosis with COVID-19. Anonymised data were submitted by clinical teams. Regression models were tested for predictors of hospitalisation and mortality outcomes. Separate analyzes compared the first and second ‘waves’ of the pandemic. Univariable analysis found hospitalisation and mortality were associated with increasing age, male gender, comorbidities, severe disability, and progressive MS; severe disability showed the highest magnitude of association. Being on a DMT was associated with a small, lower risk. Multivariable analysis found only age and male gender were significant. Post hoc analysis demonstrated that factors were significant for hospitalisation but not mortality. In the second wave, hospitalisation and mortality were lower. Separate models of the first and second wave using age and gender found they had a more important role in the second wave. Features associated with poor outcome in COVID-19 are similar to other populations and being on a DMT was not found to be associated with adverse outcomes, consistent with smaller studies. Once in hospital, no factors were predictive of mortality. Reassuringly, mortality appears lower in the second wave.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2021.103317